ÖZKAN, T. A. Et Al. 2017. Neither PSAD and Clinical T Stage, Nor Alpha Reductase Inhibitor Use Significantly Affects Pathological Progress in Geriatric Patients Under Active Surveillance for Localized Prostate Cancer. Geriatric Urological Society Annual Meeting 2017 , (BOSTON, United States Of America).

ÖZKAN, T. A., CEBECİ, O. Ö., YÜKSEKKAYA, M., KÖSEM, M. E., ŞİMŞEK, E., ÜSTÜNER, M., ... ÇEVİK, İ. H.(2017). Neither PSAD and Clinical T Stage, Nor Alpha Reductase Inhibitor Use Significantly Affects Pathological Progress in Geriatric Patients Under Active Surveillance for Localized Prostate Cancer . Geriatric Urological Society Annual Meeting 2017, BOSTON, United States Of America

ÖZKAN, TAYYAR Et Al. "Neither PSAD and Clinical T Stage, Nor Alpha Reductase Inhibitor Use Significantly Affects Pathological Progress in Geriatric Patients Under Active Surveillance for Localized Prostate Cancer," Geriatric Urological Society Annual Meeting 2017, BOSTON, United States Of America, 2017

ÖZKAN, TAYYAR A. Et Al. "Neither PSAD and Clinical T Stage, Nor Alpha Reductase Inhibitor Use Significantly Affects Pathological Progress in Geriatric Patients Under Active Surveillance for Localized Prostate Cancer." Geriatric Urological Society Annual Meeting 2017 , BOSTON, United States Of America, 2017

ÖZKAN, T. A. Et Al. (2017) . "Neither PSAD and Clinical T Stage, Nor Alpha Reductase Inhibitor Use Significantly Affects Pathological Progress in Geriatric Patients Under Active Surveillance for Localized Prostate Cancer." Geriatric Urological Society Annual Meeting 2017 , BOSTON, United States Of America.

@conferencepaper{conferencepaper, author={TAYYAR ALP ÖZKAN Et Al. }, title={Neither PSAD and Clinical T Stage, Nor Alpha Reductase Inhibitor Use Significantly Affects Pathological Progress in Geriatric Patients Under Active Surveillance for Localized Prostate Cancer}, congress name={Geriatric Urological Society Annual Meeting 2017}, city={BOSTON}, country={United States Of America}, year={2017}}